Galapagos chops into their pipeline, dropping core fields and reorganizing R&D as the BD team hunts for something 'transformative'
Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.
The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.